What dose and formulation of GnRH agonist do you use for ovarian suppression in young breast cancer patients?

Available data is largely with the monthly formulation. I don't have a strong preference for which LHRH agent (though some payers might). The q12-week depot formulation may not maintain full suppression for younger patients. Here is my pragmatic strategy

1. Start with monthly (q4 week). If not tolerat...